Clinical trialNCT05878717RecruitingPhase 2/PHASE3Interventional

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

SponsorGlaxoSmithKlineEnrollment300Scleroderma, SystemicSystemic Sclerosis Associated Interstitial Lung Disease

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

131 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Argentina

Gsk Investigational Site
Buenos Aires, Argentina
Maria Tamborenea
Recruiting
Gsk Investigational Site
Ciudad Autonoma Buenos Aires, Argentina
Maria Jose Lopez Meiller
Recruiting
Gsk Investigational Site
Ciudad Autonoma de Buenos Aire, Argentina
Anastasia Secco
Recruiting

Australia

Gsk Investigational Site
Liverpool, New South Wales, Australia
Completed
Gsk Investigational Site
Adelaide, South Australia, Australia
Susanna Proudman
Recruiting
Gsk Investigational Site
Woodville, South Australia, Australia
Maureen Rischmueller
Recruiting
Gsk Investigational Site
Fitzroy, Victoria, Australia
Wendy Stevens
Recruiting

Belgium

Gsk Investigational Site
Ghent, Belgium
Vanessa Smith
Recruiting
Gsk Investigational Site
Liège, Belgium
Julien Guiot
Recruiting

Brazil

Gsk Investigational Site
Belo Horizonte, Brazil
Wagner Moura
Recruiting
Gsk Investigational Site
Curitiba, Brazil
Completed
Gsk Investigational Site
Juiz de Fora, Brazil
Viviane Angelina de Souza
Recruiting
Gsk Investigational Site
Porto Alegre, Brazil
Adalberto Rubin
Recruiting
Gsk Investigational Site
Porto Alegre, Brazil
Mauro Waldemar Keiserman
Recruiting
Gsk Investigational Site
Salvador, Brazil
Mittermayer Santiago
Recruiting
Gsk Investigational Site
São Paulo, Brazil
Percival Barros
Recruiting
Gsk Investigational Site
São Paulo, Brazil
Cristiane K da Silva
Recruiting

China

Gsk Investigational Site
Beijing, China
Yuewu Lu
Recruiting
Gsk Investigational Site
Beijing, China
Rong Mu
Recruiting
Gsk Investigational Site
Beijing, China
Dong Xu
Recruiting
Gsk Investigational Site
Beijing, China
xuan zhang
Recruiting
Gsk Investigational Site
Changchun, China
Zhenyu Jiang
Recruiting
Gsk Investigational Site
Chengdu, China
Yi Liu
Recruiting
Gsk Investigational Site
Chengdu, China
Jing Zhu
Recruiting
Gsk Investigational Site
Luzhou, China
Chengsong He
Recruiting
Gsk Investigational Site
Mianyang, China
Jing Yang
Recruiting
Gsk Investigational Site
Nanjing, China
Lingyun Sun
Recruiting
Gsk Investigational Site
Nanjing, China
Wenfeng Tan
Recruiting
Gsk Investigational Site
Nanning, China
Jinying Lin
Recruiting
Gsk Investigational Site
Shanghai, China
LI TING
Recruiting
Gsk Investigational Site
Shanghai, China
Hejian Zou
Recruiting
Gsk Investigational Site
Shenyang, China
Pingting Yang
Recruiting
Gsk Investigational Site
Xi'an, China
Lan He
Recruiting
Gsk Investigational Site
Zhuzhou, China
Jingyang Li
Recruiting

Denmark

Gsk Investigational Site
Aarhus, Denmark
Esben Naeser
Recruiting
Gsk Investigational Site
Odense C, Denmark
Withdrawn

Finland

Gsk Investigational Site
Turku, Finland
Laura Pirila
Recruiting

France

Gsk Investigational Site
Bobigny, France
Yurdagul Uzunhan
Recruiting
Gsk Investigational Site
Brest, France
Claire de Moreuil
Recruiting
Gsk Investigational Site
Paris, France
Yannick Allanore
Recruiting

91 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 13 Sept 2023
Primary completion: 17 May 2029
Completion: 12 Jul 2029
Last update posted: 12 Jan 2026
Registered enrollment: 300
Registry id: NCT05878717

Cross-registrations

EU-CTR / CTIS (EudraCT)2023-503219-14-01

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.